

# **Antiviral Therapeutics**

## **Technologies, Companies & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**June 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is the CEO and a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include a Handbook of Nanomedicine (2008, Chinese edition published by Peking University Press in 2011, 3rd ed by Springer in 2017), Textbook of Personalized Medicine (2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer 2015), Handbook of Biomarkers (2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), "Applications of Biotechnology in Cardiovascular Therapeutics" (2011), "Applications of Biotechnology in Neurology (2013)", and "Applications of Biotechnology in Oncology (2014)", all of which have been published by Springer.

**June 2018 (originally published in 2007 and continuously updated since then)  
Copyright © 2018 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:       +4161-6924461  
Email:            info@pharmabiotech.ch  
Web site:         http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>17</b>
<b>1. Introduction to Virology .....</b>	<b>19</b>
<b>Introduction.....</b>	<b>19</b>
Evolution of viruses .....	19
<b>Virus databases .....</b>	<b>19</b>
A practical classification of viruses .....	19
<b>The human virome .....</b>	<b>21</b>
Viral genomics.....	21
<b>Pathomechanism of viral diseases relevant to therapy .....</b>	<b>21</b>
Intrinsic host defense against retroviruses .....	22
Interferon-induced B cell deletion in chronic viral infections.....	23
Drosha as an interferon-independent antiviral factor .....	23
Life cycle of virus as basis for antiviral approaches.....	23
Genetic switch in virus infections .....	24
<b>Emerging viruses .....</b>	<b>25</b>
<b>Viral-induced cancer .....</b>	<b>26</b>
<b>Viral encephalitis .....</b>	<b>27</b>
Antibody-mediated encephalitis .....	27
Brain's response to viral infections .....	27
Combination of antivirals with immunosuppression in viral encephalitis.....	28
<b>Molecular diagnosis of viral diseases .....</b>	<b>28</b>
<b>Prophylaxis versus therapy.....</b>	<b>29</b>
<b>Economic impact of viral diseases.....</b>	<b>29</b>
<b>Historical landmarks in the development of antiviral therapies .....</b>	<b>29</b>
<b>2. Antiviral Approaches.....</b>	<b>31</b>
<b>Classification .....</b>	<b>31</b>
<b>Antiviral drug discovery and development .....</b>	<b>31</b>
Antiviral drug targets – viral versus cellular .....	31
Antivirals based on double-stranded RNA activated caspase oligomerizer.....	33
Antimicrobial peptides .....	33
Human DDX3 protein as a target for developing broad spectrum antiviral agents .....	33
<b>Immunological approaches .....</b>	<b>34</b>
Basics of immune regulation in relation to viruses .....	34
<i>Effect of viruses on the immune system.....</i>	<i>34</i>
<i>Latent viral infections and the immune system .....</i>	<i>35</i>
Immunomodulating agents.....	35
<i>Amplification of innate immunity .....</i>	<i>35</i>
<i>Blocking the effects of thromboxane A2 on thromboxane receptor.....</i>	<i>36</i>
<i>Enhancers of immune system .....</i>	<i>36</i>
<i>Promoting immune-mediated clearance of a chronic viral infections.....</i>	<i>36</i>
<i>Immunoglobulins .....</i>	<i>37</i>
<i>Bovine lactoferrin.....</i>	<i>37</i>
<i>Quercetin .....</i>	<i>38</i>
Monoclonal antibodies .....	38
<i>Antibody production technologies.....</i>	<i>39</i>
<i>Bavituximab .....</i>	<i>39</i>
<i>Treatment of viral infection with radiolabeled MAbs .....</i>	<i>39</i>
<i>Limitations of MAbs and measures to overcome these .....</i>	<i>40</i>
Interferon-based approaches.....	40
Cholesterol-25-hydroxylase.....	41
<b>Novel antiviral approaches .....</b>	<b>41</b>
Phosphatidylethanolamine inhibitors as potential antivirals.....	41
Squalamine .....	41
Synthetic modified hypericin compounds.....	42
Targeting Toll-like receptors .....	42
<i>Potential and drawbacks of TLR-ligands in viral diseases .....</i>	<i>43</i>
<b>Inhibition of viral transport from cytoplasm into the cell nucleus.....</b>	<b>43</b>
<b>Nitric Oxide based antiviral therapeutics .....</b>	<b>43</b>
<b>Amino acid cognate anticodon binding specificity.....</b>	<b>44</b>
<b>Antisense approaches to viral infections.....</b>	<b>44</b>
Antisense oligonucleotides .....	44
Limitations of antisense oligonucleotides as antivirals .....	45
Phosphorodiamidate morpholino oligomers.....	46
<b>Gene therapy for viral infections.....</b>	<b>46</b>
<b>RNAi.....</b>	<b>46</b>

RNAi screens of viral genomes .....	47
RNAi for treatment of viral infections .....	47
Promise and pitfalls of RNAi gene therapy .....	48
<b>Role of proteomics in virology .....</b>	<b>48</b>
Interaction of proteins with viruses .....	49
Quantitative temporal viromics .....	49
<b>Management of rapidly evolving pathogens .....</b>	<b>49</b>
<b>Personalized medicine and viral diseases .....</b>	<b>50</b>
<b>An integrated approach to viral diseases .....</b>	<b>50</b>
<b>Current problems and needs in antiviral therapy .....</b>	<b>50</b>
Immunoinformatic approach to vaccine design for emerging infections .....	51
<b>3. Vaccines for Virus Infections .....</b>	<b>53</b>
<b>Introduction.....</b>	<b>53</b>
<b>Types of vaccines.....</b>	<b>54</b>
DNA vaccines .....	54
Live attenuated virus vaccines .....	55
mRNA vaccines.....	55
Nanotechnology-based vaccines.....	56
<i>Nanobead adjuvants.....</i>	<i>56</i>
Recombinant viral vaccines .....	56
SMART vaccines.....	57
Synthetic peptides as vaccines.....	57
Virally vectored vaccines.....	58
Virosomes.....	59
Vaccines based on reverse genetics.....	59
Virus-like particles .....	59
<b>Routine vaccination in children against viral infections .....</b>	<b>60</b>
<b>Personalized vaccines .....</b>	<b>61</b>
<b>Limitations of vaccines .....</b>	<b>61</b>
Neurological complications of vaccination .....	61
<b>Expert opinion on antiviral vaccines .....</b>	<b>62</b>
<b>4. Role of Nanotechnology in Developing Antiviral Agents.....</b>	<b>63</b>
<b>Introduction.....</b>	<b>63</b>
Study of interaction of nanoparticles with viruses.....	63
Exosomes and viral infections.....	64
<b>Nanoparticle antiviral agents .....</b>	<b>64</b>
Silver nanoparticles .....	64
Fullerenes .....	64
Nanoparticles mimic RNAi for treatment of viral infections.....	65
<b>Nanoviricides .....</b>	<b>65</b>
Role of micelles in nanopharmaceuticals .....	65
Some physicochemical characteristics common to polymeric micelles .....	66
Structure and function of nanoviricides .....	66
<i>Mechanism of action of NanoViricides .....</i>	<i>66</i>
<i>Advantages of NanoViricides.....</i>	<i>68</i>
<b>5. Delivery of Antivirals .....</b>	<b>71</b>
<b>Introduction.....</b>	<b>71</b>
<b>Methods of delivery of antiviral agents .....</b>	<b>71</b>
Local application of antivirals.....	71
Systemic delivery of of protein-polymer antiviral drugs.....	72
Controlled delivery of antivirals.....	72
Targeted delivery of antivirals .....	72
Delivery of antivirals to the brain across the blood-brain barrier.....	73
<b>Antiviral vaccine delivery systems .....</b>	<b>73</b>
Minicell vaccine delivery .....	73
Transnasal delivery of vaccines by Newcastle disease virus as vector .....	73
Transdermal delivery of vaccines .....	74
<i>Dissolvable microneedle array for vaccine delivery .....</i>	<i>74</i>
<i>Electroporation for administering DNA vaccines.....</i>	<i>74</i>
<i>HIV/AIDS vaccination by transdermal application .....</i>	<i>76</i>
<i>Microneedles for transdermal delivery of vaccines .....</i>	<i>76</i>
<i>Needle-free delivery of vaccines.....</i>	<i>76</i>
<i>Transdermal vaccines for influenza.....</i>	<i>77</i>
<b>Use of nanotechnology for improving delivery of antivirals .....</b>	<b>78</b>
Macrophage-based nanoformulated antiretroviral therapy .....	79
Improvement of antiviral vaccine delivery by nanotechnology.....	79
<i>Bacterial spores for delivery of vaccines.....</i>	<i>79</i>
<i>Chitosan-derived nanoparticles for vaccine delivery .....</i>	<i>79</i>

<i>Dendrimer-based intracellular delivery of antibodies</i> .....	80
<i>Gold nanorods for delivery of RNA immune activator molecules</i> .....	80
<i>Lipid nanoparticles for immunostimulatory RNA delivery</i> .....	80
<i>Liposomal antiviral vaccine preparations</i> .....	81
<i>Nanoparticles for DNA vaccines</i> .....	81
<i>Nanospheres for controlled release of viral antigens</i> .....	81
<i>Proteosomes™ as vaccine delivery vehicles</i> .....	82
<i>Polymeric micellae for delivery of DNA vaccine</i> .....	82
<i>"Smart" nanoparticles for delivery of vaccines</i> .....	82
Nanocoating for local viricidal effect .....	82
<b>Delivery of gene-based antiviral drugs</b> .....	<b>83</b>
<b>Limitations of delivery of gene, RNAi and antisense therapies</b> .....	<b>83</b>
<b>Systemic delivery of NanoViricides</b> .....	<b>84</b>
<b>Concluding remarks on delivery of antiviral agents</b> .....	<b>84</b>
<b>6. Competitive Assessment of Antiviral Approaches</b> .....	<b>85</b>
<b>Introduction</b> .....	<b>85</b>
<b>An ideal antiviral agent</b> .....	<b>85</b>
<b>SWOT analysis</b> .....	<b>85</b>
<b>Concluding remarks</b> .....	<b>88</b>
<b>7. Influenza Viruses</b> .....	<b>89</b>
<b>Introduction</b> .....	<b>89</b>
<b>Clinical features of influenza</b> .....	<b>89</b>
Colds due to rhinovirus .....	89
Effects of influenza on the respiratory system .....	90
Effect of avian influenza on the nervous system .....	90
<b>Epidemiology</b> .....	<b>90</b>
Supermap of avian influenza .....	90
Influenza A .....	91
Avian influenza affecting humans .....	91
<i>Human infection with a H7N9 Virus</i> .....	92
Human influenza versus avian influenza .....	92
H1N1 influenza .....	93
<b>Immune system and influenza</b> .....	<b>94</b>
Immune Epitope Database and Analysis Resources .....	95
Role of Tpl2 in antiviral host defense mechanisms .....	95
<b>Anti-influenza approaches</b> .....	<b>96</b>
Pharmaceuticals .....	96
Neuraminidase inhibitors .....	96
<i>Mechanism of action</i> .....	96
<i>Tamiflu</i> .....	97
<i>Zanamivir</i> .....	97
<i>CS-8958</i> .....	97
<i>Peramivir</i> .....	98
<i>Resistance to neuraminidase inhibitors</i> .....	99
<i>Adverse effects of neuraminidase inhibitors</i> .....	99
<i>Concluding remarks on neuraminidase inhibitors</i> .....	100
Other drugs for influenza .....	100
<i>Adamantanes</i> .....	100
<i>Probenecid</i> .....	101
Current recommendations for the use of antiviral agents for influenza .....	101
Vaccines .....	101
<i>Seasonal influenza vaccines</i> .....	101
<i>Live attenuated influenza vaccine vs. inactivated vaccine</i> .....	102
<i>Recombinant influenza vaccine</i> .....	103
<i>Vaccines for H1N1 influenza</i> .....	103
<i>Vaccines for H7N9 influenza</i> .....	104
Current status of influenza vaccines .....	104
<i>Current recommendations for influenza vaccination</i> .....	104
<i>Current status of vaccine preparedness against seasonal influenza</i> .....	105
<i>Current status of vaccine preparedness against H5N1</i> .....	105
Limitations, needs and challenges of influenza vaccines .....	106
<i>Limitations of current influenza vaccines</i> .....	106
<i>Needs of influenza vaccines</i> .....	106
<i>Problems with demand and supply of influenza vaccines</i> .....	107
<i>Problems with access to virus samples</i> .....	108
<i>FluVac project for development of pandemic influenza vaccine</i> .....	108
<i>Influenza vaccines for multiple strains of influenza</i> .....	108
<i>Quadrivalent influenza vaccine</i> .....	109
<i>Universal influenza vaccines</i> .....	109

<i>Future of influenza vaccines</i> .....	110
Application of new technologies for influenza vaccines .....	110
<i>Adjuvants</i> .....	111
<i>Cell culture-derived influenza vaccines</i> .....	112
<i>DNA vaccines for avian influenza</i> .....	113
<i>Epitope-based vaccines for influenza</i> .....	113
<i>Gene-based vaccines for influenza</i> .....	114
<i>Live attenuated vaccines</i> .....	114
<i>MAbs for passive immunization against avian influenza</i> .....	114
<i>M2e-based human influenza A vaccine</i> .....	114
<i>RNA vaccines against influenza A</i> .....	115
<i>Pre-pandemic split antigen H5N1 vaccine</i> .....	115
<i>Recombinant-protein based influenza vaccines</i> .....	116
<i>Synthetic avian influenza vaccine</i> .....	117
<i>Viral vectors for influenza vaccination</i> .....	117
<i>Virus-like particles as influenza vaccines</i> .....	117
RNAi-based approaches .....	119
<i>Inhibition of influenza virus by siRNAs</i> .....	119
<i>Limitations of RNAi approach to influenza</i> .....	120
<i>Challenges and future prospects of siRNAs for influenza</i> .....	120
Antisense approaches .....	120
<i>NEUGENE® antisense for inhibition of multiple strains of influenza A</i> .....	121
Nanoviricides against influenza .....	121
Other innovative approaches .....	122
<i>Abatacept</i> .....	122
<i>Polymeric coatings to inactivate influenza virus</i> .....	122
<i>Cytotoxic therapy</i> .....	123
<i>Cyanovirin</i> .....	123
<i>Fludase</i> .....	123
<i>Mulfiferon®</i> .....	123
<i>Pyrrolidine dithiocarbamate</i> .....	124
<i>Value of antivirals in preventing spread of influenza after exposure</i> .....	124
<i>Resistance to influenza therapy and efforts to overcome it</i> .....	125
FLUCURE project.....	125
NIAID Centers of Excellence for research on pandemic influenza viruses .....	125
Research on influenza viruses at Bayer .....	126
Concluding remarks and future .....	126

<b>8. AIDS/HIV .....</b>	<b>129</b>
<b>Introduction.....</b>	<b>129</b>
<b>Epidemiology .....</b>	<b>129</b>
<b>Current concepts of pathomechanisms .....</b>	<b>129</b>
Decoding the structure of an entire HIV genome .....	130
Genetic basis of resistance against HIV .....	130
Host-pathogen interactions that regulate HIV-1 replication.....	130
Pathogenesis of AIDS .....	131
Visualization of the interaction of HIV-1 proteins with target cells .....	132
Viral latency in HIV .....	132
<b>Complications of AIDS .....</b>	<b>133</b>
AIDS and the nervous system .....	133
AIDS wasting syndrome.....	133
Coexistent HIV-1 and HSV-2 .....	134
Coexistent hepatitis virus infections with HIV.....	134
<i>HIV and HBV</i> .....	134
<i>HIV and HCV</i> .....	134
Opportunistic infections in AIDS.....	135
<i>HIV and tuberculosis</i> .....	136
<b>Current therapies.....</b>	<b>136</b>
Aim of anti-HIV drugs.....	137
Nucleoside reverse transcriptase inhibitors .....	138
Non-nucleoside reverse transcriptase inhibitors .....	139
<i>Efavirenz</i> .....	139
<i>Etravirine</i> .....	139
Protease inhibitors .....	139
<i>Tipranavir</i> .....	139
<i>Darunavir</i> .....	139
Fusion inhibitors .....	140
<i>Enfuvirtide</i> .....	140
<b>Impact of antiretroviral treatment on transmission of HIV .....</b>	<b>140</b>
Preexposure prophylaxis against HIV .....	141
Postexposure prophylaxis against HIV .....	142

Antiretroviral therapy in early asymptomatic HIV infection .....	142
<b>Limitations of current therapies.....</b>	<b>142</b>
Adverse effects of antiretroviral therapy .....	143
Drug resistance in AIDS .....	144
Effect of interruption of HIV treatment.....	144
Reservoirs of HIV Infection.....	145
Persistence of low-level viremia in HIV-1 patients on retroviral therapy .....	145
<b>Reconsideration of abandoned therapies for AIDS.....</b>	<b>145</b>
<b>Therapies in development.....</b>	<b>145</b>
Drugs in development for HIV/AIDS .....	145
<i>NRTIs in development</i> .....	146
<i>NNRIs in development</i> .....	147
Novel protease inhibitors .....	147
<i>Overcoming HIV-1 resistance to PIs</i> .....	147
<i>PPL-100</i> .....	148
Entry inhibitors targeting CCR5 receptor .....	148
<i>Maraviroc</i> .....	149
<i>SP-01A</i> .....	149
<i>MABs targeting CCR5 receptor</i> .....	150
<i>PRO 140</i> .....	150
<i>Ibalizumab</i> .....	151
Integrase inhibitors .....	151
<i>Raltegravir (Isentress)</i> .....	151
<i>Elvitegravir</i> .....	152
<i>Dolutegravir</i> .....	152
<i>S/GSK1265744</i> .....	153
<i>LEDGINS</i> .....	153
Design of fusion inhibitor peptides against enfuvirtide-resistant HIV-1 .....	153
Maturation inhibitors .....	154
Blocking of pre-integration complex translocation .....	154
Immune enhancers .....	154
Pyrimidinediones.....	155
Combinations of drugs for AIDS .....	156
<i>Truvada</i> .....	156
<i>Raltegravir, enfuvirtide, and darunavir</i> .....	156
<b>Other innovative antiviral approaches against HIV/AIDS .....</b>	<b>156</b>
A filtration device for HIV-1 as an adjunct to the immune system .....	156
Anti-HIV therapies based on editing enzymes .....	156
Anti-HIV activity of drugs that stimulate cholesterol efflux .....	157
Antiviral hyperactivation-limiting therapeutics .....	157
ATR kinase as a target for anti-HIV drug discovery.....	157
Blocking of HIV budding by DC-SIGN protein.....	157
Drugs from natural sources .....	158
Enhancing immune response by blockade of PD-1 receptor .....	158
IL-2 as adjunct to antiretroviral therapy.....	159
In vitro evaluation of antiviral drug activity .....	159
Methods for sustaining antiviral activity .....	159
Microbicidal agents for local application in HIV/AIDS.....	160
<i>Investigational microbicides against HIV and their limitations</i> .....	160
<i>CCR5 receptor blockers</i> .....	161
<i>P5C-Rantes and recombinant chemokine analogs</i> .....	161
<i>HIV-1 entry inhibitor griffithsin as a topical microbicide</i> .....	162
<i>Nanotechnology-based topical microbicides</i> .....	162
<i>Next generation microbicides for HIV</i> .....	162
<i>Vaginal application of anti-retroviral drugs against HIV</i> .....	162
Nanoviricides for HIV/AIDS .....	163
Prophylactic measures to prevent HIV infection .....	163
Selective targeting of ITK to block multiple steps of HIV replication .....	164
<b>Cell therapy for HIV/AIDS .....</b>	<b>164</b>
hESCs converted to T cells for treatment of HIV infection .....	164
Transplantation of genetically modified hematopoietic cells .....	165
Transplantation of genetically modified T cells .....	165
Overlapping Peptide-pulsed Autologous Cells.....	165
<b>Gene therapy strategies in HIV/AIDS .....</b>	<b>166</b>
Gene editing for HIV-1.....	166
Inhibition of HIV-1 replication by lentiviral vectors .....	167
VRX496-T (Lexgenleucel-T) .....	167
Insertion of protective genes into target cells .....	168
Use of genes to chemosensitize HIV-1 infected cells .....	168
Autocrine interferon- $\beta$ production by somatic cell gene therapy.....	168
Intracellular immunization in HIV .....	168

<i>Engineered cellular proteins such as soluble CD4s</i> .....	169
<i>Intracellular antibodies</i> .....	169
<i>Selection of T cell vaccine antigens</i> .....	169
<i>Glycoprotein 120 as target for neutralizing HIV-1 antibodies</i> .....	169
<i>Anti-rev single chain antibody fragment</i> .....	170
HIV/AIDS vaccines .....	170
<i>Cell-based vaccines for HIV</i> .....	171
<i>Delivery of HIV vaccine by an adenoviral vector</i> .....	171
<i>DNA vaccines for HIV/AIDS</i> .....	172
<i>Epitope-based DNA vaccines against HIV</i> .....	173
<i>Gene transfer for HIV vaccination</i> .....	173
<i>Recombinant HIV proteins</i> .....	173
<i>Vaccination after discontinuation of antiretroviral treatment</i> .....	174
Innovations in HIV/AIDS vaccine.....	174
<i>Attenuated rabies virus-based vaccine for HIV</i> .....	174
<i>Dendritic cell-based vaccine for HIV</i> .....	174
<i>DermaVir</i> .....	175
<i>Early control of HIV by an effector memory T cell vaccine</i> .....	175
<i>Immunogens for inducing broadly neutralizing antibodies</i> .....	176
<i>MVA nef vaccine</i> .....	176
<i>Peptide-based vaccine for HIV</i> .....	176
<i>Personalized vaccine for HIV</i> .....	177
<i>RV144 HIV vaccine trial</i> .....	177
<i>Transdermal nanoparticles for immune enhancement in HIV</i> .....	177
<i>Vaccine to prevent HIV entry at the mucosal level</i> .....	178
Limitations and future of HIV vaccines .....	178
Antisense approaches to AIDS .....	179
<i>Antisense oligodeoxynucleotides</i> .....	179
<i>Antisense efforts with PNA constructs</i> .....	179
<i>RNA decoys</i> .....	180
<i>Ribozymes</i> .....	180
RNAi applications in HIV/AIDS .....	181
<i>A multiple shRNA approach for silencing of HIV-1</i> .....	181
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i> .....	182
<i>Bispecific siRNA constructs</i> .....	182
<i>Role of the nef gene during HIV-1 infection and RNAi</i> .....	182
<i>siRNA-directed inhibition of HIV-1 infection</i> .....	183
<i>Synergistic effect of snRNA and siRNA</i> .....	184
<i>Targeting CXCR4 with siRNAs</i> .....	184
<i>Targeting CCR5 with siRNAs</i> .....	184
<i>Concluding remarks on RNAi approach to HIV/AIDS</i> .....	185
Companies involved in developing gene therapy for HIV/AIDS .....	185
Conclusions regarding gene therapy of HIV/AIDS .....	186
<b>Testing for new anti-HIV therapies</b> .....	<b>186</b>
<b>Personalized approach to management of HIV</b> .....	<b>187</b>
Differences in response of the body to HIV .....	187
Variations in action of drugs on HIV .....	187
<i>Drug-resistance in HIV</i> .....	188
<i>PhenoSense® to test HIV drug resistance</i> .....	188
<i>Role of biomarkers in management of HIV/AIDS</i> .....	188
<i>Role of diagnostic testing in management of HIV</i> .....	189
<i>Prevention of adverse reactions to antiviral drugs</i> .....	189
<i>Nanoviricides as a personalized approach to HIV</i> .....	190
<b>Concluding remarks and future</b> .....	<b>190</b>
<b>9. Hepatitis Viruses</b> .....	<b>193</b>
<b>Introduction</b> .....	<b>193</b>
<b>Hepatitis delta virus infection</b> .....	<b>193</b>
<b>Hepatitis A virus infection</b> .....	<b>193</b>
<b>Hepatitis E virus infection</b> .....	<b>194</b>
Epidemiology .....	194
Structure of the HEV .....	194
Treatment of HEV infection.....	194
<i>Ribavirin</i> .....	194
<i>HEV vaccines</i> .....	195
<b>Epidemiology of HBV</b> .....	<b>195</b>
<b>Pathogenesis of HBV-induced liver disease</b> .....	<b>195</b>
<b>Current approaches to management of HBV</b> .....	<b>196</b>
Entecavir .....	197
Adefovir dipivoxil .....	197
Telbivudine .....	197



Pegylated interferon-alpha .....	198
<b>Limitations of current therapies and needs of HBV .....</b>	<b>198</b>
<b>Personalized management of HBV .....</b>	<b>198</b>
<b>Innovations in the management of HBV .....</b>	<b>199</b>
Tenofovir disoproxil fumarate .....	199
Hepatitis B immune globulins .....	199
<i>Nabi-HB</i> .....	199
<i>HepaGam B</i> .....	200
Hepatitis B vaccine composed in a novel nanoemulsion adjuvant .....	200
Innovative pharmaceuticals for HBV .....	200
<i>AGX-1009</i> .....	200
<i>Clevudine</i> .....	201
<i>Helioxanthin analog 8-1</i> .....	201
<i>HepDirect prodrugs</i> .....	201
Monoclonal antibodies for HBV .....	201
RNAi-based therapy of HBV .....	202
Personalized treatment of hepatitis B .....	202
Concluding remarks and future prospects of management of hepatitis B .....	203
<b>Epidemiology of HCV .....</b>	<b>203</b>
<b>HCV characteristics .....</b>	<b>203</b>
<b>Pathomechanism of HCV infection .....</b>	<b>204</b>
Mechanism of HCV entry .....	204
HCV and the immune system .....	204
Mechanism of HCV replication and response to interferon .....	204
<b>Current approaches to management of HCV .....</b>	<b>205</b>
Interferon therapy for HCV .....	205
Limitations of current HCV therapies .....	205
<b>Novel approaches to HCV .....</b>	<b>206</b>
HCV protease inhibitors .....	207
<i>ABT-450</i> .....	207
<i>Boceprevir</i> .....	207
<i>Combined daclatasvir and asunaprevir</i> .....	207
<i>Faldaprevir</i> .....	208
<i>Glecaprevir/pibrentasvir combination</i> .....	208
<i>Narlaprevir</i> .....	208
<i>Sofosbuvir</i> .....	208
<i>Simeprevir</i> .....	208
<i>Small molecule HCV protease inhibitors</i> .....	209
<i>Telaprevir</i> .....	209
Innovations in interferon therapy for HCV .....	210
<i>AlbIFN-<math>\alpha</math>2b</i> .....	210
<i>Directed evolution of gene-shuffled IFN-<math>\alpha</math> for treatment of HCV</i> .....	210
<i>GEA007.1</i> .....	210
<i>Omega DUROS</i> .....	211
<i>PEG-IFN-<math>\lambda</math></i> .....	211
<i>Personalizing interferon therapy of HCV</i> .....	212
Innovative ribavirin-based treatments .....	212
<i>Targeted delivery of hemoglobin-ribavirin conjugate for HCV</i> .....	212
<i>Taribavirin</i> .....	212
Nucleoside polymerase inhibitor .....	213
<i>Deleobuvir</i> .....	213
<i>Valopicitabine</i> .....	213
Host cell targets for hepatitis C therapy .....	213
<i>SP-10</i> .....	214
NS5a inhibitors .....	214
<i>Ledipasvir</i> .....	214
NS5b inhibitors .....	214
Novel combination of a protease inhibitor and a NS5a inhibitor .....	215
<i>Zepatier™</i> .....	215
Compounds targeting HCV receptor E2 .....	215
Cyclophilin inhibitors .....	215
<i>Alisporivir</i> .....	216
Methylene blue .....	216
Naringenin .....	216
Nitazoxanide .....	217
Cyclosporine and analogs as anti-HCV agents .....	217
Clemizole and HCV .....	218
RNAi-based approaches to HCV .....	218
<i>Use of adenoviral vectors for RNAi</i> .....	218
<i>siRNAs for HCV</i> .....	219
<i>Limitations and drawbacks of siRNA therapy for HCV</i> .....	219

<i>Role of miRNA in viral infections</i> .....	220
<i>miR-122 antagonists</i> .....	220
Gene therapy for HCV.....	220
Vaccines for HCV .....	221
<i>HCV vaccine based on viral vectors to boost T cell memory</i> .....	221
<i>Vaccine based on neutralizing antibodies to HCV</i> .....	221
Clinical trials of HCV therapeutics.....	222
Limitations to the development of effective anti-HCV therapeutics.....	222
<i>Causes of treatment failure in chronic hepatitis C</i> .....	223
<i>HCV drug resistance</i> .....	223
<b>Personalized management of HCV infection</b> .....	<b>223</b>
Role of sequencing in personalized management of HCV .....	224
<b>Concluding remarks about HCV therapy</b> .....	<b>225</b>
Drug combinations for HCV .....	225
IFN-free combinations for HCV.....	225
Search for new drugs for HCV.....	226
<b>Future needs in HCV therapy</b> .....	<b>226</b>
<b>10. Miscellaneous Commercially Important Virus Infections</b> .....	<b>229</b>
<b>Introduction</b> .....	<b>229</b>
<b>Herpes viruses</b> .....	<b>229</b>
Neuroinvasive herpesviruses .....	229
Herpes simplex virus .....	229
Treatment of HSV-1 .....	229
<i>Acyclovir</i> .....	229
<i>Vaccines for HSV</i> .....	230
<i>Antisense therapy for HSV-1</i> .....	230
Herpes simplex virus 2 and genital herpes .....	231
<i>Famciclovir</i> .....	231
<i>Pritelivir</i> .....	231
<i>Intravaginal microbicial agents for HSV-2</i> .....	231
<i>Vaccines for HSV-2</i> .....	232
Herpes simplex keratitis.....	232
Herpes simplex encephalitis .....	233
Limitations of current HSV therapies.....	233
<i>Genomic diversity of HSV-1 as a cause of failure of vaccines</i> .....	233
Herpes zoster virus .....	234
<i>Herpes zoster and chicken pox</i> .....	234
<i>Epidemiology of herpes zoster</i> .....	234
<i>Treatment of herpes zoster</i> .....	234
<i>Herpes zoster vaccines</i> .....	235
Epstein-Barr virus .....	235
Latent herpes virus infection .....	236
<b>Cytomegalovirus</b> .....	<b>236</b>
Current treatment of CMV .....	237
<i>Brincidofovir (CMX001)</i> .....	237
<i>Valganciclovir hydrochloride</i> .....	237
<i>Limitations of current treatment and future</i> .....	237
Letermovir .....	237
T cell therapy for CMV .....	238
Vaccines for CMV .....	238
Gene therapy of CMV.....	239
Antisense approach to CMV .....	239
siRNA treatment of CMV.....	240
<b>Human papilloma virus</b> .....	<b>240</b>
Epidemiology.....	240
Vaccines for HPV .....	241
<i>Gardasil</i> .....	241
<i>Cervarix</i> .....	241
<i>DNA vaccine VGX-3100</i> .....	242
<i>GTL001 and GTL002</i> .....	242
<i>Vaccine based on fusion proteins of HPV envelope</i> .....	242
<i>Limitations of HPV vaccines</i> .....	242
Antivirals for HPV .....	243
<i>Imiquimod</i> .....	243
Novel approaches against HPV .....	243
<i>Intrabody strategies for the treatment of HPV</i> .....	243
<i>A novel peptide to inhibit HPV</i> .....	244
<i>Heat shock protein-based antivirals</i> .....	244
<b>Respiratory syncytial virus</b> .....	<b>245</b>
Epidemiology.....	245

Current management of RSV .....	245
<i>Palivizumab</i> .....	245
<i>MDT-637</i> .....	246
<i>GS-5806</i> .....	246
<i>RNAi approach to RSV</i> .....	246
<i>Other approaches to RSV antivirals</i> .....	247
Vaccines for RSV .....	247
<i>BCG as a vaccine against RSV</i> .....	247
<i>Oral DNA vaccine for RSV</i> .....	247
<i>Neutralizing antibodies against preactive form of hRSV_F protein</i> .....	248
Challenges for development of RSV antivirals .....	248
<b>Other respiratory viruses .....</b>	<b>248</b>
Parainfluenzavirus type 3 .....	248
Human metapneumovirus .....	248
<b>Gastrointestinal viruses .....</b>	<b>249</b>
Noroviruses .....	249
<i>Potential for development of antiviral agents against noroviruses</i> .....	250
<i>Vaccines against noroviruses</i> .....	250
<b>Concluding remarks .....</b>	<b>251</b>
<b>11. Viruses with High Impact but Low Commercial Significance .....</b>	<b>253</b>
<b>Introduction .....</b>	<b>253</b>
<b>Chikungunya fever .....</b>	<b>253</b>
Chikungunya antiviral therapy .....	254
Chikungunya vaccines .....	254
<b>Enteroviruses .....</b>	<b>254</b>
Enterovirus 71 .....	254
Coxsackie virus .....	255
<b>Japanese encephalitis .....</b>	<b>255</b>
Vaccines for JE .....	255
<b>Parvovirus .....</b>	<b>256</b>
<b>Polyomavirus JC .....</b>	<b>256</b>
<b>Rabies .....</b>	<b>257</b>
Rabies vaccines .....	257
<i>Recombinant viral vaccines for rabies</i> .....	258
DNA vaccine against rabies .....	258
Rabies immune globulin .....	258
Monoclonal antibodies for rabies .....	258
NanoViricides approach for rabies .....	259
Protein-protein interactions as targets for antirabies drug discovery .....	259
siRNA-based approach against rabies .....	259
The Milwaukee protocol for rabies .....	260
<b>Rotavirus .....</b>	<b>260</b>
Epidemiology .....	260
Rotavirus genome .....	260
Vaccines against rotavirus .....	261
<b>Viral hemorrhagic fevers .....</b>	<b>262</b>
Bas-Congo virus associated with acute hemorrhagic fever .....	263
Crimean-Congo hemorrhagic fever .....	263
Dengue .....	264
<i>Epidemiology</i> .....	264
<i>Antivirals in development</i> .....	265
<i>Dengue vaccines</i> .....	266
<i>Elimination of dengue vector mosquitoes by fungus</i> .....	268
<i>Genetic elimination of dengue vector mosquitoes</i> .....	268
Ebola virus .....	268
<i>Pathogenesis and diagnosis of Ebola virus</i> .....	269
<i>Sequencing of the Ebola genome</i> .....	269
<i>Antiviral approaches to Ebola virus infection</i> .....	270
<i>Antivirals for Ebola based on inhibition of RNA polymerase</i> .....	271
<i>Cell entry blockers as antivirals for filoviruses</i> .....	271
<i>Development of RNAi-based antiviral drugs for Ebola</i> .....	272
<i>EbolaCide</i> .....	272
<i>Monoclonal antibody immunotherapy for Ebola</i> .....	273
<i>Vaccines for Ebola</i> .....	273
<i>Ebola whole virus vaccine</i> .....	276
<i>Companies developing antivirals against Ebola</i> .....	276
<i>Concluding remarks and future</i> .....	276
Human hanta viruses .....	277
Lassa fever .....	278
Marburg hemorrhagic fever .....	278

<i>Therapies in development against Marburg virus</i> .....	278
Yellow fever .....	279
<i>Vaccines for yellow fever</i> .....	279
<i>Sequencing of Aedes aegypti genome and control of yellow fever</i> .....	280
<b>West Nile virus</b> .....	<b>280</b>
Epidemiology.....	280
Pathogenesis .....	280
Treatment of West Nile neuroinvasive disease .....	281
Vaccines against WNV .....	281
Innovative treatments for WNV.....	282
<b>Zika virus</b> .....	<b>282</b>
Introduction to Zika virus.....	282
ZIKV in the USA.....	283
Clinical features of ZIKV.....	283
Molecular epidemiology of ZIKV .....	283
Molecular diagnosis of ZIKV infection.....	283
Neurological complications of ZIKV infection .....	284
<i>Microcephaly</i> .....	284
<i>Guillain-Barré syndrome</i> .....	285
Prevention and treatment of ZIKV infection .....	285
<i>Antiviral agents against ZIKV</i> .....	285
<i>Preventive measures against ZIKV infection</i> .....	286
<i>Vaccines for ZIKV</i> .....	286
<i>WHO views on challenges in management of ZIKV</i> .....	288
<b>Western equine encephalitis</b> .....	<b>289</b>
<b>Tick-borne encephalitis</b> .....	<b>289</b>
TBE vaccines .....	289
<b>Human coronaviruses</b> .....	<b>289</b>
SARS.....	289
<i>Therapeutic approaches to SARS</i> .....	290
<i>MABs for SARS</i> .....	290
<i>siRNA treatment of SARS</i> .....	291
Middle East respiratory syndrome coronavirus .....	291
<i>Development of therapeutics for MERS-CoV</i> .....	293
<i>MERS vaccines</i> .....	294
<i>Future directions for management of MERS</i> .....	295
<b>Measles</b> .....	<b>295</b>
<b>Zoonotic viral infections</b> .....	<b>296</b>
Nipah virus.....	296
Vaccines for zoonotic viral diseases .....	296
<b>Virus bioterrorism and biowarfare</b> .....	<b>297</b>
Small pox as a biological weapon .....	297
<i>Status of small pox vaccination</i> .....	297
Strategies against virus bioterrorism and biowarfare .....	298
<i>Increasing resistance by stimulating innate immune mechanisms</i> .....	298
<i>Nanoviricides for combating viral bioterrorism</i> .....	298
<b>Concluding remarks</b> .....	<b>299</b>
<b>12. Markets for Antivirals</b> .....	<b>301</b>
<b>Introduction</b> .....	<b>301</b>
<b>Markets according to disease</b> .....	<b>301</b>
Influenza market .....	301
HIV/AIDS market.....	302
Hepatitis B and C markets.....	303
<i>Economics of care of hepatitis C and impact on the market</i> .....	303
Markets for diseases with low commercial significance .....	303
<b>Markets according to products and approaches</b> .....	<b>304</b>
<b>Market values of monoclonal antibodies for viral diseases</b> .....	<b>304</b>
<b>Market values of vaccines for viral diseases</b> .....	<b>304</b>
Markets for vaccines against HPV .....	305
Research investment and potential markets for HIV/AIDS vaccines .....	305
Markets for other antiviral vaccines .....	305
<b>Markets according to geographical areas</b> .....	<b>305</b>
Emerging markets for antiviral therapeutics .....	306
Geographical distribution of HIV/AIDS market .....	307
<b>Unmet needs in antivirals</b> .....	<b>307</b>
<b>Policies regarding conquered viral diseases</b> .....	<b>308</b>
Future of polio vaccine.....	308
<b>Policies concerning HPV vaccine for prevention of cervical cancer</b> .....	<b>309</b>
<i>HPV vaccine in developing countries</i> .....	309
<b>Future prospects of innovative approaches</b> .....	<b>310</b>

US Government support of antiviral efforts.....	311
<i>US Government support for R &amp; D in avian influenza vaccines</i> .....	311
<i>US Government support for developing anti-bioterrorism agents</i> .....	311
The European Union support of antiviral research.....	312
<i>European Commission's research support for anti-HIV/AIDS programs</i> .....	312
<i>European Commission's support anti-influenza programs</i> .....	313
Collaboration of biotechnology companies with big pharma .....	314
<b>Strategies for marketing .....</b>	<b>314</b>
<b>13. Companies .....</b>	<b>315</b>
<b>Introduction.....</b>	<b>315</b>
<b>Top companies .....</b>	<b>315</b>
<b>Profiles of pharmaceutical companies.....</b>	<b>316</b>
<b>Profiles of biopharmaceutical companies with antiviral products .....</b>	<b>332</b>
<b>Profiles of antiviral drug companies.....</b>	<b>419</b>
<b>Profiles of viral vaccine companies .....</b>	<b>448</b>
<b>Collaborations.....</b>	<b>530</b>
<b>14. References.....</b>	<b>537</b>
<b>Tables</b>	
Table 1-1: A practical classification of viruses.....	20
Table 1-2: Viruses causing encephalitis .....	27
Table 1-3: Vaccines vs therapeutics for viral diseases.....	29
Table 1-4: Historical landmarks in the development of antiviral therapies .....	29
Table 2-1: Classification of antiviral strategies.....	31
Table 2-2: Viral vs cellular targets for discovery of antivirals .....	32
Table 2-3: Viruses amenable to antisense oligonucleotides.....	45
Table 2-4: Inhibition of viral replication by RNAi .....	47
Table 3-1: Types of vaccines for viral diseases .....	54
Table 4-1: Role of nanobiotechnology in virology .....	63
Table 5-1: Methods of delivery of antiviral agents .....	71
Table 5-2: Role of nanotechnology for improving delivery of antivirals.....	78
Table 5-3: Commercially available liposomal antiviral vaccines .....	81
Table 6-1: SWOT of monoclonal antibodies .....	85
Table 6-2: SWOT of agents that prevention viral entry into cells .....	86
Table 6-3: SWOT of drugs interfering with intracellular replication .....	86
Table 6-4: SWOT of protease inhibitors .....	86
Table 6-5: SWOT of integrase inhibitors.....	86
Table 6-6: SWOT of maturation inhibitors .....	86
Table 6-7: SWOT of neuraminidase inhibitors .....	87
Table 6-8: SWOT of targeting Toll-like receptors (TLRs).....	87
Table 6-9: SWOT of topical antivirals agents against viral infections.....	87
Table 6-10: SWOT of gene therapy, antisense oligonucleotides, RNAi .....	87
Table 6-11: SWOT of vaccines .....	87
Table 6-12: SWOT of NanoViricides.....	88
Table 7-1: Anti-influenza approaches .....	96
Table 7-2: Antiviral drugs used for influenza .....	96
Table 7-3: Various approaches to production of influenza vaccines.....	111
Table 8-1: Drugs in clinical development for HIV/AIDS .....	146
Table 8-2: Strategies for gene therapy of AIDS .....	166
Table 8-3: Classification of HIV/AIDS vaccines in clinical trials.....	170
Table 8-4: Companies involved in developing gene therapy for HIV/AIDS .....	185
Table 9-1: Innovations in the treatment of HBV .....	199
Table 9-2: Innovations for management of HCV .....	206
Table 9-3: Antiviral agents for HCV targeting host cells .....	213
Table 9-4: HCV drugs in clinical trials .....	222
Table 10-1: Methods of delivery of acyclovir.....	230
Table 11-1: Antiviral strategies against Ebola virus infection .....	270
Table 11-2: Companies developing antiviral products against Ebola .....	276
Table 11-3: ZIKA vaccines in development.....	287
Table 11-4: Strategies against virus bioterrorism and biowarfare.....	298
Table 12-1: Worldwide market for all antiviral approaches 2017-2027 .....	301
Table 12-2: Markets for antiviral drugs according to virus infections 2017-2027 .....	301
Table 12-3: Markets values of all drugs for HIV/AIDS 2017-2027.....	302
Table 12-4: Market values of monoclonal antibodies for viral diseases 2017-2027.....	304
Table 12-5: Market values of vaccines for viral diseases 2017-2027 .....	304
Table 12-6: Markets for antiviral drugs according to geographical areas 2017-2027 .....	306
Table 12-7: Markets for antiviral vaccines according to geographical areas 2017-2027 .....	306
Table 12-8: Emerging markets for antiviral drugs according to countries 2017-2027 .....	306
Table 12-9: Emerging markets for antiviral vaccines according to countries 2017-2027 .....	307

Table 13-1: Top antiviral companies.....	315
Table 13-2: Roche antiviral products in development .....	322
Table 13-3: Collaborations of antiviral companies .....	530

## Figures

Figure 1-1: Varieties of host and cell responses to viral infections .....	22
Figure 1-2: Cycle of infection and replication of a retrovirus .....	24
Figure 1-3: Viral-induced cancer .....	26
Figure 2-1: An integrated approach to viral diseases .....	50
Figure 4-1: Schematic representation of NanoViricide attacking a virus particle .....	67
Figure 7-1: Evolution of mutations associated with virulence/drug resistance in H5N1 .....	93
Figure 7-2: Mechanism of development of resistance to oseltamivir .....	99
Figure 8-1: Mode of action of some current anti-HIV drugs .....	137
Figure 8-2: Nanocarrier-mediated siRNA delivery for treatment of HIV/AIDS .....	184
Figure 9-1: Steps of HBV replication and site of action of various drugs .....	196
Figure 9-2: Omega DUROS device for interferon delivery in chronic hepatitis C.....	211
Figure 11-1: Ebola virus .....	269
Figure 11-2: Strategies for development of ZIKV vaccines .....	287
Figure 11-3: Transmission and pathogenesis of MERS-CoV.....	293
Figure 12-1: Unmet needs in antivirals .....	308